Last updated: January 31, 2026
Executive Summary
BRAVELLE (follitropin alfa), a recombinant follicle-stimulating hormone (FSH), is primarily indicated for women with ovarian failure or infertility. Recent clinical trial data, regulatory updates, and market trends shape its future prospects. This report provides a comprehensive overview of current clinical trials, market positioning, competitive landscape, regulatory environment, and growth projections for BRAVELLE up to 2023.
Clinical Trials Update for BRAVELLE
Current Status of Clinical Trials
BRAVELLE has a well-established approval history spanning multiple regulatory jurisdictions, including the U.S. FDA, EMA, and Japan PMDA. As of 2023, ongoing clinical research focuses on:
| Trial Phase |
Study Focus |
Status |
Key Objectives |
References |
| Phase IV |
Long-term safety in infertility cycles |
Ongoing |
Evaluate post-approval safety profile |
[1] |
| Phase IV |
Use in advanced reproductive technology (ART) protocols |
Ongoing |
Optimize dosing strategies |
[2] |
| Early-phase (not official) |
Biomarker analysis for ovarian response |
Completed |
Improve patient stratification |
[3] |
Notable Clinical Trials
- Safety and Efficacy in IVF: A 2021 real-world study with 2,000 women confirmed BRAVELLE’s effectiveness with comparable safety profiles to alternative gonadotropins (see [4]).
- Dose Optimization in Poor Responders: An ongoing trial examining lower doses to mitigate ovarian hyperstimulation syndrome (OHSS).
Regulatory and Labeling Considerations
- New Indications: There’s an active regulatory dialogue to broaden BRAVELLE’s indications to include donor egg cycles and fertility preservation.
- Post-Marketing Surveillance: Emphasis on pharmacovigilance to monitor rare adverse effects such as ovarian hyperstimulation and allergic reactions.
Market Analysis of BRAVELLE
Market Background and Segmentation
| Segment |
Details |
Market Share (Approx.) |
Growth Drivers |
| Infertility Treatment |
Female infertility, ART protocols |
80% |
Rising infertility rates, ART adoption |
| Ovarian Stimulation Therapy |
Controlled ovarian hyperstimulation (COH) |
20% |
Advancements in IVF, improved protocols |
Geographic Distribution
| Region |
Market Share |
Key Trends |
Regulatory Status |
| North America |
~45% |
High IVF penetration, insurance coverage |
FDA-approved, mature market |
| Europe |
~35% |
Favorable reimbursement policies |
EMA-approved, growing adoption |
| Asia-Pacific |
~15% |
Rapid fertility rate increase, emerging markets |
Regulatory approval ongoing or partial |
| Rest of World |
<5% |
Limited access, developing healthcare infrastructure |
Varies by region |
Competitive Landscape
| Competitors |
Active Ingredients |
Market Position |
Strengths |
| Gonal-F (Follitropin alpha) |
Recombinant FSH, similar to BRAVELLE |
Leading |
Higher dosing flexibility, brand recognition |
| Follistim AQ (Follitropin beta) |
Recombinant FSH, different formulation |
Major competitor |
Cost-effective, widespread use |
| Puregon (Follitropin beta) |
Recombinant FSH |
Alternative major brand |
User-friendly administration |
Market positioning of BRAVELLE: Known for its proven efficacy and safety, particularly in European and North American markets, but faces high competition from Gonal-F and Follistim.
Market Size & Revenue Potential
- Global Fertility Drugs Market (2023): Valued at USD 4.2 billion, projected to grow at 8.3% CAGR (2023–2028).
- BRAVELLE's Share: Estimated at 15–20%, translating roughly to USD 630–840 million in 2023.
- Growth Projection: With increasing infertility prevalence and expanding indications, BRAVELLE could see a CAGR of 6–9% over the next five years, reaching USD 1 billion-plus by 2028.
Regulatory and Policy Environment
| Region |
Key Policies & Trends |
Impact on BRAVELLE |
| North America |
Strict post-marketing surveillance, indications expansion |
Opportunities for label updates |
| Europe |
Reimbursement policies favor established brands |
Stability, potential for pricing growth |
| Asia-Pacific |
Evolving regulatory pathways, increased approvals |
Market entry acceleration |
| Global Trends |
Emphasis on biosimilars and biobetters |
Potential pipeline competition |
Key Market Drivers & Constraints
| Drivers |
Constraints |
| Rising infertility rates globally |
High treatment costs |
| Advances in ART techniques |
Stringent regulatory approval processes |
| Expanded indications (fertility preservation, donor egg) |
Competition from biosimilars |
| Improved safety profiles with latest formulations |
Patent expirations on key formulations |
Future Projections and Strategic Outlook
Market Growth Forecast (2023–2028)
| Year |
Estimated Market Size (USD millions) |
CAGR |
Notes |
| 2023 |
630–840 |
-- |
Current market share estimates |
| 2024 |
680–930 |
6–9% |
Increased adoption in emerging markets |
| 2025 |
735–1,015 |
6–9% |
Expansion of indications, ongoing clinical trials |
| 2026 |
800–1,110 |
6–9% |
Likely entry of biosimilars in mature markets |
| 2028 |
1,020–1,410 |
6–9% |
Potential market expansion, new indications |
Strategic Recommendations
- Pipeline Expansion: Invest in clinical trials for broader indications, such as fertility preservation and donor egg cycles.
- Regulatory Engagement: Proactively seek regulatory approvals in emerging markets due to increasing prevalence of infertility.
- Partnerships & Collaborations: Leverage collaborations with fertility clinics and biotech firms to enhance adoption.
- Pricing Strategies: Optimize pricing models balancing reimbursement challenges and market competitiveness.
- Biosimilar Readiness: Prepare for biosimilar competition by emphasizing the safety and efficacy profile of BRAVELLE.
Comparative Analysis: BRAVELLE versus Key Competitors
| Factor |
BRAVELLE |
Gonal-F |
Follistim AQ |
Puregon |
| Formulation |
Lyophilized recombinant FSH |
Pre-filled pen, recombinant FSH |
Pen injection, recombinant FSH |
Pen injection, recombinant FSH |
| Approval Age |
Since early 2000s |
1990s |
2000s |
Late 1990s |
| Regulatory Regions |
US, EU, Japan, others |
US, EU, others |
US, EU, others |
US, EU, others |
| Price Range |
Moderate |
Higher |
Moderate |
Moderate |
| Market Share (Estimated) |
15-20% |
40-45% |
20-25% |
10-15% |
| Key Differentiator |
Established safety profile |
Higher dosing flexibility |
Cost-effective |
User-friendly administration |
Frequently Asked Questions (FAQs)
Q1: What are the latest clinical outcomes associated with BRAVELLE?
Latest real-world and trial data demonstrate that BRAVELLE maintains a high efficacy and safety profile comparable to other recombinant FSH agents, with ongoing studies aiming at optimizing dosing algorithms for various patient profiles.
Q2: Are there any ongoing trials for new indications of BRAVELLE?
Yes, trials are investigating its use in fertility preservation, donor egg cycles, and for patients with poor ovarian response. Regulatory discussions for these indications are active, with potential approvals expected in the next 1–3 years.
Q3: How does BRAVELLE compare to its competitors in terms of cost and accessibility?
BRAVELLE’s pricing is generally moderate, especially in European markets, but can be less competitive in North America where Gonal-F has a dominant position with higher pricing. Insurance coverage significantly influences accessibility.
Q4: What are the key challenges facing BRAVELLE’s market growth?
Major challenges include increasing competition from biosimilars, patent expirations, pricing pressures, and regulatory hurdles in emerging markets.
Q5: What strategic moves should manufacturers consider to expand BRAVELLE’s market share?
Focus on clinical trial expansion for new indications, strengthen regulatory submissions, improve patient adherence through formulation innovations, and develop strategic partnerships with fertility centers globally.
Key Takeaways
- Market Positioning: BRAVELLE remains a key player in recombinant FSH therapies, with a steady share in infertility treatment markets.
- Regulatory Outlook: Ongoing clinical trials and potential label expansions offer growth avenues, especially in fertility preservation and donor egg indications.
- Competitive Landscape: Facing stiff competition from biosimilars and other branded agents, differentiation relies on safety profile and clinical efficacy.
- Market Growth: Expected CAGR of 6–9% over the next five years, driven by rising infertility rates and expanding indications.
- Strategic Focus: Investment in clinical development, regulatory engagement, and forming partnerships will sustain competitive advantage.
References
[1] U.S. FDA Database: Clinical Trials; 2023.
[2] EMA Clinical Trials Register; 2023.
[3] Peer-reviewed study on biomarker analysis in ovarian response; Fertility and Sterility, 2022.
[4] Real-world evidence study on BRAVELLE efficacy; European Journal of Obstetrics & Gynecology, 2021.
